PMID- 33942287
OWN - NLM
STAT- MEDLINE
DCOM- 20211216
LR  - 20240320
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 194
IP  - 1
DP  - 2021 Jul
TI  - Current and emerging therapeutic approaches for T-cell acute lymphoblastic 
      leukaemia.
PG  - 28-43
LID - 10.1111/bjh.17310 [doi]
AB  - T-cell ALL (T-ALL) is an aggressive malignancy of T-cell progenitors. Although 
      survival outcomes in T-ALL have greatly improved over the past 50 years, relapsed 
      and refractory cases remain extremely challenging to treat and those who cannot 
      tolerate intensive treatment continue to have poor outcomes. Furthermore, T-ALL 
      has proven a more challenging immunotherapeutic target than B-ALL. In this review 
      we explore our expanding knowledge of the basic biology of T-ALL and how this is 
      paving the way for repurposing established treatments and the development of 
      novel therapeutic approaches.
CI  - (c) 2021 The Authors. British Journal of Haematology published by British Society 
      for Haematology and John Wiley & Sons Ltd.
FAU - Pocock, Rachael
AU  - Pocock R
AUID- ORCID: 0000-0002-0051-1965
AD  - Department of Haematology, UCL Cancer Institute, University College London, 
      London, UK.
FAU - Farah, Nadine
AU  - Farah N
AUID- ORCID: 0000-0002-3945-9981
AD  - Department of Haematology, UCL Cancer Institute, University College London, 
      London, UK.
FAU - Richardson, Simon E
AU  - Richardson SE
AUID- ORCID: 0000-0003-4343-4784
AD  - Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, 
      UK.
AD  - Department of Haematology, University of Cambridge, Jeffrey Cheah Biomedical 
      Centre, Cambridge, UK.
FAU - Mansour, Marc R
AU  - Mansour MR
AUID- ORCID: 0000-0001-6835-3791
AD  - Department of Haematology, UCL Cancer Institute, University College London, 
      London, UK.
LA  - eng
GR  - C67279/A27957/CRUK_/Cancer Research UK/United Kingdom
GR  - 203151/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - 26238/CRUK_/Cancer Research UK/United Kingdom
GR  - 27957/CRUK_/Cancer Research UK/United Kingdom
GR  - DRCPLT-NOV20100001/CRUK_/Cancer Research UK/United Kingdom
GR  - 17002/LLR_/Blood Cancer UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210503
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Arabinonucleosides)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Janus Kinase Inhibitors)
RN  - 0 (NOTCH1 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Receptor, Notch1)
RN  - 0 (Receptors, Interleukin-7)
RN  - 0 (Sulfonamides)
RN  - 60158CV180 (nelarabine)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinases)
RN  - N54AIC43PW (venetoclax)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Antineoplastic Agents, Immunological/therapeutic use
MH  - Apoptosis/drug effects
MH  - Arabinonucleosides/therapeutic use
MH  - Bridged Bicyclo Compounds, Heterocyclic/therapeutic use
MH  - Cyclin-Dependent Kinases/antagonists & inhibitors
MH  - Genetic Heterogeneity
MH  - Humans
MH  - Immunotherapy
MH  - Immunotherapy, Adoptive
MH  - Janus Kinase Inhibitors/therapeutic use
MH  - Molecular Targeted Therapy
MH  - Neoplasm Proteins/antagonists & inhibitors
MH  - Phosphoinositide-3 Kinase Inhibitors/therapeutic use
MH  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/genetics/*therapy
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Receptor, Notch1/antagonists & inhibitors
MH  - Receptors, Interleukin-7/antagonists & inhibitors
MH  - Salvage Therapy/methods
MH  - Signal Transduction/drug effects
MH  - Sulfonamides/therapeutic use
MH  - Therapies, Investigational/methods/trends
MH  - Treatment Outcome
OTO - NOTNLM
OT  - leukaemia
OT  - novel treatments
EDAT- 2021/05/05 06:00
MHDA- 2021/12/17 06:00
CRDT- 2021/05/04 07:03
PHST- 2021/05/05 06:00 [pubmed]
PHST- 2021/12/17 06:00 [medline]
PHST- 2021/05/04 07:03 [entrez]
AID - 10.1111/bjh.17310 [doi]
PST - ppublish
SO  - Br J Haematol. 2021 Jul;194(1):28-43. doi: 10.1111/bjh.17310. Epub 2021 May 3.